Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -25.92% is 21% below its 5-year average of -21.36%, around the middle of its 5-year range (-67.67%–37.42%).
304.09% below its 12-month average of 12.70%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.59%.
RETURN ON ASSETS (ROA)
-25.92%
RETURN ON ASSETS (ROA) AVG TTM
12.70%
RETURN ON ASSETS (ROA) AVG 3Y
-8.51%
RETURN ON ASSETS (ROA) AVG 5Y
-21.36%
RETURN ON ASSETS (ROA) AVG 10Y
-42.24%
RETURN ON ASSETS (ROA) AVG 15Y
-43.92%
RETURN ON ASSETS (ROA) AVG 20Y
-38.53%
CURRENT VS TTM AVG
-304.09%
CURRENT VS 3Y AVG
-204.49%
CURRENT VS 5Y AVG
-21.36%
CURRENT VS 10Y AVG
+38.63%
CURRENT VS 15Y AVG
+40.98%
CURRENT VS 20Y AVG
+32.73%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+19.60%
vs the sector median at left
Novavax, Inc.
Market Cap
$1.80B
Return on Assets (ROA)
-25.92%
TTM Avg
12.70%
3Y Avg
-8.51%
5Y Avg
-21.36%
Market Cap
$1.80B
Return on Assets (ROA)
-61.53%
TTM Avg
-47.53%
3Y Avg
-47.53%
5Y Avg
-47.53%
Market Cap
$1.80B
Return on Assets (ROA)
-22.53%
TTM Avg
-17.47%
3Y Avg
-13.86%
5Y Avg
-9.24%
Market Cap
$1.82B
Return on Assets (ROA)
10.25%
TTM Avg
8.68%
3Y Avg
8.17%
5Y Avg
8.38%
Market Cap
$1.79B
Return on Assets (ROA)
-45.02%
TTM Avg
-50.76%
3Y Avg
-46.27%
5Y Avg
-37.50%
Market Cap
$1.83B
Return on Assets (ROA)
-4.29%
TTM Avg
-7.68%
3Y Avg
-13.57%
5Y Avg
-14.36%
Market Cap
$1.78B
Return on Assets (ROA)
-18.68%
TTM Avg
-15.27%
3Y Avg
-14.09%
5Y Avg
-9.93%
Market Cap
$1.85B
Return on Assets (ROA)
-44.98%
TTM Avg
-76.52%
3Y Avg
-94.59%
5Y Avg
-76.85%
Market Cap
$1.77B
Return on Assets (ROA)
-1.10%
TTM Avg
-1.54%
3Y Avg
-1.02%
5Y Avg
-1.23%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novavax, Inc. (NVAX) | $1.80B | -25.92% | 12.70% | -8.51% | -21.36% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.80B | -61.53% | -47.53% | -47.53% | -47.53% |
| Xencor, Inc. (XNCR)vs › | $1.80B | -22.53% | -17.47% | -13.86% | -9.24% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 10.25% | 8.68% | 8.17% | 8.38% |
| Absci Corporation (ABSI)vs › | $1.79B | -45.02% | -50.76% | -46.27% | -37.50% |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | -4.29% | -7.68% | -13.57% | -14.36% |
| Novocure Ltd (NVCR)vs › | $1.78B | -18.68% | -15.27% | -14.09% | -9.93% |
| Immunome, Inc. (IMNM)vs › | $1.85B | -44.98% | -76.52% | -94.59% | -76.85% |
| Surgery Partners, Inc. (SGRY)vs › | $1.77B | -1.10% | -1.54% | -1.02% | -1.23% |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 1.78% | 2.10% | 3.84% | 3.40% |
ROA
-25.9%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 37.42% |
| 2024-12-31 | -12.02% |
| 2023-12-31 | -30.32% |
| 2022-12-31 | -29.13% |
| 2021-12-31 | -67.67% |
| 2020-12-31 | -26.43% |
| 2019-12-31 | -75.22% |
| 2018-12-31 | -88.83% |
| 2017-12-31 | -60.75% |
| 2016-12-31 | -71.00% |
| 2015-12-31 | -40.65% |
| 2014-12-31 | -30.05% |
| 2013-12-31 | -22.03% |
| 2012-12-31 | -27.85% |
| 2011-12-31 | -29.09% |
| 2010-12-31 | -47.71% |
| 2009-12-31 | -44.83% |
| 2008-12-31 | -47.05% |
| 2007-12-31 | -38.08% |
| 2006-12-31 | -18.93% |
| 2005-12-31 | -13.24% |
| 2004-12-31 | -33.23% |
| 2003-12-31 | -20.52% |
| 2002-12-31 | -39.47% |
| 2001-12-31 | -14.52% |
| 2000-12-31 | -21.57% |
| 1999-12-31 | -100.00% |
| 1998-12-31 | -126.32% |
| 1997-12-31 | -66.18% |
| 1996-12-31 | -96.49% |
